Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclarubicin Combined With Azacitidine and Venetoclax in AML
NCT07486726Phase 2Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aclarubicin in acute myeloid leukemia (AML), sponsored by Shanghai Jiao Tong University School of Medicine. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
aclarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07486726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486726.